Pharmacological Approach to Improve the Outcome of Social Cognition Training
27 mars 2013 mis à jour par: Stephen R Marder, MD, VA Greater Los Angeles Healthcare System
This study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of Social Cognitive Skills Training (SCST).
The primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater improvements in a summary measure of social cognition than subjects treated with placebo over the course of SCST.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
Individuals with schizophrenia often have serious deficits in their abilities to perceive and interpret socially relevant information. These deficits in social cognition can lead to misunderstanding the intentions of others and failing to interpret social signals that are important for successful social interactions. The relationship between social cognition and functioning has led our group to develop a research agenda that includes understanding the neural underpinnings of social cognitive deficits, measuring these impairments using brain-based biomarkers and clinical assessments, and enhancing our Social Cognitive Skills Training program to improve social cognition and promote recovery.
Oxytocin, which is a hormone and neurotransmitter, is believed to impact social cognition through increased orienting toward and attending to socially salient visual features. There is also evidence that oxytocinergic signaling is impaired in schizophrenia. With this research, we hope to learn whether administration of oxytocin will improve different aspects of social cognition by examining the effects of oxytocin versus placebo administered intranasally before each of 12 sessions of a social cognitive skills training program on measures of independent living, work and social functioning.
Type d'étude
Interventionnel
Inscription (Réel)
27
Phase
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
California
-
Los Angeles, California, États-Unis, 90073
- West Los Angeles VA Medical Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 55 ans (Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Homme
La description
Inclusion Criteria:
- Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition
- Stable on an antipsychotic medication
- No change in antipsychotic dose of >10% during the past 3 months
Exclusion Criteria:
- Unable to provide informed consent
- History of epilepsy
- Active medical conditions that would make the study unsafe
- History of serious head injury
- History of hyponatremia
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Placebo+Social Cognitive Skills Training
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
The treatment groups will include individuals who are assigned to placebo.
Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
|
Placebo, matched to Oxytocin, intranasal inhalation
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
|
|
Expérimental: Oxytocin+Social Cognitive Skill Training
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
The treatment groups will include individuals who are assigned to oxytocin.
Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
|
The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation.
These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice.
The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks.
Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
Oxytocin 40 IU, intranasal inhalation
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Composite Social Cognition Score
Délai: Baseline, 6 weeks, and 10 weeks
|
We will assess emotion management, emotion perception, social context processing/social perception, theory of mind, attributional bias, and empathic accuracy.
The primary summary measure for each test will be mean-centered and standardized to create a Z-score that will be averaged to create a single composite score for social cognition, serving as the primary outcome measure.
Parallel follow-up analyses will be conducted on individual components to determine which measures are most affected by treatment.
Similar secondary analyses will be employed for the event related potential (ERP) and basic cognition measures.
|
Baseline, 6 weeks, and 10 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Stephen R Marder, MD, Department of Veterans Affairs, University of California Los Angeles
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010 Oct 1;68(7):678-80. doi: 10.1016/j.biopsych.2010.04.039. Epub 2010 Jul 7.
- Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, Lebell M, Zimmerman K, Liberman RP. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry. 1996 Dec;153(12):1585-92. doi: 10.1176/ajp.153.12.1585.
- Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M, Marder SR, Green MF. Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res. 2011 Aug;45(8):1113-22. doi: 10.1016/j.jpsychires.2011.01.015. Epub 2011 Mar 4.
- Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol. 2009 Oct;30(4):548-557. doi: 10.1016/j.yfrne.2009.05.005. Epub 2009 Jun 6.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 janvier 2012
Achèvement primaire (Réel)
1 février 2013
Achèvement de l'étude (Réel)
1 février 2013
Dates d'inscription aux études
Première soumission
19 janvier 2012
Première soumission répondant aux critères de contrôle qualité
19 janvier 2012
Première publication (Estimation)
25 janvier 2012
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
29 mars 2013
Dernière mise à jour soumise répondant aux critères de contrôle qualité
27 mars 2013
Dernière vérification
1 mars 2013
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Promise # 0041
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .